A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

S-217622

Tablet for oral administration

Trial Locations (4)

Orlando Clinical Research Center, Inc., Orlando

Clinical Pharmacology of Miami, LLC, Miami

Advanced Pharma CR, LLC, Miami

Nucleus Network, Saint Paul